Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: A molecular based approach using T-cell receptor γ and δ gene rearrangements

Haematologica

Volumn 87, Issue 11, 2002, Pages 1126-1134

  Gameiro, Paula ^a   Mortuza, Forioa Y ^a   Hoffbrand, A Victor ^a   Foroni, Letizia ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adult lymphoblastic leukemia; MRD; T cell ALL; TCR and genes

Indexed keywords

T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT DISEASE; ARTICLE; BONE MARROW BIOPSY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MONITORING; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; T CELL LEUKEMIA;

ADOLESCENT; ADULT; BONE MARROW; FEMALE; GENE REARRANGEMENT; GENES, T-CELL RECEPTOR DELTA; GENES, T-CELL RECEPTOR GAMMA; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0036854345     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591-8.
2. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352:1731-8.
3. Blondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000;14:1939-43.
4. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000; 95:790-4.
5. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99:1253-8.
6. Willemse MJ, Seriu T, Hettinger K, d'Aniello E, Hop WC, Panzer-Grumayer ER, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99:4386-93.
7. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96:2691-6.
8. Ciudad J, San Miguel JF, Lopez-Berges MC, Vidriales B, Valverde B, Ocqueteau M, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998; 16:3774-81.
9. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98:1746-51.
10. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 1993; 82:1618-25.
11. Salo A, Pakkala S, Jansson SE, Helminen P, Palotie A. Monitoring of adult B-cell lineage acute lymphoblastic leukemia: Validation of a simple method for detecting immunoglobulin heavy chain gene clonality. Leukemia 1993; 7:1459-65.
12. Scholten C, Fodinger M, Mitterbauer M, Laczika K, Mitterbauer G, Haas OA, et al. Kinetics of minimal residual disease during induction/consolidation therapy in standardrisk adult B-lineage acute lymphoblastic leukemia. Ann Hematol 1995; 71:155-60.
13. Brisco J, Hughes E, Neoh SH, Sykes PJ, Bradstock K, Enno A, et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996; 87:5251-6.
14. Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Sinclair MF, Chim JS, et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997; 11:1732-41.
15. Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20:1094-104.
16. Dibenedetto SP, Lo Nigro L, Di Cataldo A, Schiliro G. Detection of minimal residual disease: Methods and relationship to outcome in T-lineage acute lymphoblastic leukemia. Leuk Lymphoma 1998; 32:65-75.
17. Neale GA, Menarguez J, Kitchingman GR, Fitzgerald TJ, Koehler M, Mirro J Jr, et al. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 1991; 78:739-47.
18. Durrant IJ, Richards SM, Prentice HG, Goldstone AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000; 14:1327-52.
19. Porfiri E, Secker-Walker LM, Hoffbrand AV, Hancock JF. DCC tumor suppressor gene is inactivated in hematologic malignancies showing monosomy 18. Blood 1993; 81:2696-701.
20. Yokota S, Hansen-Hagge TE, Ludwig WD, Reiter A, Raghavachar A, Kleihauer E, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991; 77:331-9.
21. Takihara Y, Tkachuk D, Michalopoulos E, Champagne E, Reimann J, Minden M, et al. Sequence and organization of the diversity, joining, and constant region genes of the human T-cell delta-chain locus. Proc Natl Acad Sci USA 1988; 85:6097-101.
22. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13:110-8.
23. LeFranc MP, Forster A, Baer R, Stinson MA, Rabbitts TH. Diversity and rearrangement of the human T cell rearranging γ genes: Nine germ-line variable genes belonging to two subgroups. Cell 1986; 45:237-46.
24. Huck S, Lefranc MP. Rearrangements to the JP1, JP and JP2 segments in the human T-cell rearranging γ gene (TRG γ) locus. FEBS Lett 1987; 224:291-6.
25. Huck S, Dariavach P, Lefranc MP. Variable region genes in the human T-cell rearranging γ (TRG) locus: V-J junction and homology with the mouse genes. Embo J 1988; 7:719-26.
26. Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 1997; 11:2192-9.
27. Chim JC, Coyle LA, Yaxley JC, Cole-Sinclair MF, Cannell PK, Hoffbrand VA, et al. The use of IgH fingerprinting and ASO-dependent PCR for the investigation of residual disease (MRD) in ALL. Br J Haematol 1996; 92:104-15.
28. Lefranc MP, Giudicelli V, Ginestoux C, Bodmer J, Muller W, Bontrop R, et al. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 1999; 27:209-12.
29. Szczepanski T, Langerak AW, Willemse MJ, Wolvers-Tettero IL, van Wering ER, van Dongen JJ. T cell receptor γ (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia refelct 'end-stage' recombinations: Implications for minimal residual disease monitoring. Leukemia 2000; 14:1208-14.
30. Delabesse E, Burtin ML, Millien C, Madonik A, Arnulf B, Beldjord K, et al. Rapid, multifluorescent TCRG Vγ and Jγ typing: Application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populations. Leukemia 2000; 14:1143-52.
31. Szczepanski T, Langerak AW, Wolvers-Tettero IL, Ossenkoppele GJ, Verhoef G, Stul M, et al. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: Implications for selection of PCR targets for detection of minimal residual disease. Leukemia 1998; 12:1081-8.
32. Breit TM, Wolvers-Tettero IL, Beishuizen A, Verhoeven MA, van Wering ER, van Dongen JJ. Southern blot patterns, frequencies, and junctional diversity of T-cell receptor-delta gene rearrangements in acute lymphoblastic leukemia. Blood 1993; 82(10):3063-74.
33. Seeger K, Taube T, Eckert C, Hanel C, Pogodda M, Henze G. Unusual T-cell receptor-delta gene rearrangement patterns revealed by screening of a large series of childhood acute lymphoblastic leukaemia by multiplex polymerase chain reaction. Br J Haematol 2001; 113:318-22.
34. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92:4072-9.
35. Pui CH, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14:2286-94.
36. Foroni L, Harrison CJ, Hoffbrand AV, Potter MN. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol 1999; 105:7-24.
37. Bruggemann M, Droese J, Bolz I, Luth P, Pott C, von Neuhoff N, et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 2000; 14:1419-25.
38. van der Velden VH, Willemse MJ, van der Schoot CE, Hahlen K, van Wering ER, van Dongen JJ. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002; 16:928-36.
39. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk B, Ribeiro RC, et al. Comparative analysis of minimal residual disease in peripheral blood versus bone marrow in childhood acute lymphoblastic leukaemia. Blood, 2001 American Society of Haematology, Orlando, USA, Abstract 3497.
40. Mackall CL, Punt JA, Morgan P, Farr AG, Gress RE. Thymic function in young/old chimeras: Substantial thymic T cell regenerative capacity despite irreversible age-associated thymic involution. Eur J Immunol 1998; 28:1886-93.
41. Steffens CM, Al-Harthi L, Shott S, Yogev R, Landay A. Evaluation of thymopoiesis using T cell receptor excision circles (TRECs): Differential correlation between adult and pediatric TRECs and naive phenotypes. Clin Immunol 2000; 97:95-101.